Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
ALL ORDINARIES finishes lower Tuesday: 8 shares you missed
Share Fallers
Why Cochlear Limited just invested $24 million in a sleep apnea treatment business
Technology Shares
Why I think the REA Group Limited (ASX:REA) share price can continue to climb
Share Market News
3 blue-chip healthcare shares for long-term growth
Share Gainers
Why UBS thinks this is the time to buy CSL Limited (ASX:CSL) shares
Share Market News
US litigant claims Cochlear Ltd (ASX:COH) can't escape US$268 million fine
Share Fallers
Why Cochlear Ltd is among 4 shares falling today
Share Fallers
The CSL Limited (ASX:CSL) share price is falling
Share Market News
ALL ORDINARIES finishes lower Monday: 8 shares you missed
Healthcare Shares
Better Buy: Cochlear Limited (ASX:COH) vs. CSL Limited (ASX:CSL)
Share Fallers
Why these 4 ASX shares have started the week in the red
Share Fallers
Cochlear Limited (ASX:COH) share price sinks lower on patent infringement news
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
